MSD and the European Organisation for Research and Treatment of Cancer (EORTC) have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival (RFS) in patients with high-risk stage III melanoma.
The Health and Social Care Committee has voiced “serious concerns” about NHS Digital’s ability to protect patient data, after reviewing its Memorandum of Understanding with the Home Office that allows data sharing to trace immigration offenders.
Warning bells for the NHS are ringing again after the latest performance data showed the highest number of emergency admissions since records began and more patients than ever before waiting more than four hours for treatment.
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.